End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4,800 KRW | -0.10% |
|
-1.84% | -15.79% |
2023 | Korea Arlico Pharm Co.,Ltd. announced that it has received KRW 10 billion in funding | CI |
2023 | Korea Arlico Pharm Co.,Ltd. announced that it expects to receive KRW 10 billion in funding | CI |
Business Summary
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 167,737 | 100.0 % | 187,155 | 100.0 % | +11.58% |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
100.0
%
| 167,737 | 100.0 % | 187,155 | 100.0 % | +11.58% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Hang-Gu Lee
CEO | Chief Executive Officer | 63 | - |
Chan-Sub Kim
BRD | Director/Board Member | 58 | 19-03-13 |
Yong-Hwa Lee
AUD | Comptroller/Controller/Auditor | 56 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Hang-Gu Lee
CEO | Chief Executive Officer | 63 | - |
Chan-Sub Kim
BRD | Director/Board Member | 58 | 19-03-13 |
Moon-Sung Lee
BRD | Director/Board Member | 57 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 15,327,021 | 8,862,074 ( 57.82 %) | 313,630 ( 2.046 %) | 57.82 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
313,630 | 2.05% | 1,106,556 $ |
Company contact information
Korea Arlico Pharm Co., Ltd.
Arlico Pharmaceutical Building 7-21 Baumeo-ro 27-gil
06752, Seoul
+
http://www.arlico.co.kr![address Korea Arlico Pharm Co.,Ltd.(A260660)](https://cdn.zonebourse.com/static/address/64310619.png)
Sector
1st Jan change | Capi. | |
---|---|---|
-15.79% | 53.12M | |
+20.76% | 43.59B | |
+28.00% | 22.54B | |
+20.25% | 15.73B | |
+18.82% | 14.33B | |
+55.83% | 12.75B | |
-0.05% | 6.79B | |
-12.70% | 6.48B | |
-8.87% | 5.73B | |
+14.65% | 5.67B |
- Stock Market
- Equities
- A260660 Stock
- Company Korea Arlico Pharm Co.,Ltd.